"Rituximab/chemistry"[MAJR] - Search Results

Year	Number of Results
2015	15
2016	12
2017	10
2018	9
2019	17
2020	9
2021	5
2022	2
2024	0

1

Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab.

Rougé L, Chiang N, Steffek M, Kugel C, Croll TI, Tam C, Estevez A, Arthur CP, Koth CM, Ciferri C, Kraft E, Payandeh J, Nakamura G, Koerber JT, Rohou A. Rougé L, et al. Science. 2020 Mar 13;367(6483):1224-1230. doi: 10.1126/science.aaz9356. Epub 2020 Feb 20. Science. 2020. PMID: 32079680

2

Binding mechanisms of therapeutic antibodies to human CD20.

Kumar A, Planchais C, Fronzes R, Mouquet H, Reyes N. Kumar A, et al. Science. 2020 Aug 14;369(6505):793-799. doi: 10.1126/science.abb8008. Science. 2020. PMID: 32792392

3

Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.

Lee KH, Lee J, Bae JS, Kim YJ, Kang HA, Kim SH, Lee SJ, Lim KJ, Lee JW, Jung SK, Chang SJ. Lee KH, et al. MAbs. 2018 Apr;10(3):380-396. doi: 10.1080/19420862.2018.1433976. Epub 2018 Mar 6. MAbs. 2018. PMID: 29469653 Free PMC article.

4

Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.

Li H, Zhang G, Jiang C, Zhang F, Ke C, Zhao H, Sun Y, Zhao M, Chen D, Zhu X, Zhang L, Li B, Dai J, Li W. Li H, et al. Oncotarget. 2015 Sep 15;6(27):24192-204. doi: 10.18632/oncotarget.4206. Oncotarget. 2015. PMID: 26284588 Free PMC article.

5

Chemoenzymatic Glyco-engineering of Monoclonal Antibodies.

Giddens JP, Wang LX. Giddens JP, et al. Methods Mol Biol. 2015;1321:375-87. doi: 10.1007/978-1-4939-2760-9_25. Methods Mol Biol. 2015. PMID: 26082235 Free PMC article.

6

Concentration and Glycoform of Rituximab in Plasma of Patients with B Cell Non-Hodgkin's Lymphoma.

Yonezawa A, Otani Y, Kitano T, Mori M, Masui S, Isomoto Y, Tsuda M, Imai S, Ikemi Y, Denda M, Sato Y, Nakagawa S, Omura T, Nakagawa T, Yano I, Hayakari M, Takaori-Kondo A, Matsubara K. Yonezawa A, et al. Pharm Res. 2019 Apr 15;36(6):82. doi: 10.1007/s11095-019-2624-5. Pharm Res. 2019. PMID: 30989405 Free article.

7

A developed antibody-drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line.

Abdollahpour-Alitappeh M, Hashemi Karouei SM, Lotfinia M, Amanzadeh A, Habibi-Anbouhi M. Abdollahpour-Alitappeh M, et al. Artif Cells Nanomed Biotechnol. 2018;46(sup2):1-8. doi: 10.1080/21691401.2018.1449119. Epub 2018 Mar 9. Artif Cells Nanomed Biotechnol. 2018. PMID: 29523024

8

Preparation and preliminary bioevaluation studies of ⁶⁸ Ga-NOTA-rituximab fragments as radioimmunoscintigraphic agents for non-Hodgkin lymphoma.

Suman SK, Kameswaran M, Pandey U, Sarma HD, Dash A. Suman SK, et al. J Labelled Comp Radiopharm. 2019 Oct;62(12):850-859. doi: 10.1002/jlcr.3803. Epub 2019 Sep 10. J Labelled Comp Radiopharm. 2019. PMID: 31461549

9

Rituximab (anti-CD20)-modified AZD-2014-encapsulated nanoparticles killing of B lymphoma cells.

Tang X, Xie C, Jiang Z, Li A, Cai S, Hou C, Wang J, Liang Y, Ma D. Tang X, et al. Artif Cells Nanomed Biotechnol. 2018;46(sup2):1063-1073. doi: 10.1080/21691401.2018.1478844. Epub 2018 Sep 8. Artif Cells Nanomed Biotechnol. 2018. PMID: 30198340

10

Rational Design of Biobetters with Enhanced Stability.

Courtois F, Schneider CP, Agrawal NJ, Trout BL. Courtois F, et al. J Pharm Sci. 2015 Aug;104(8):2433-40. doi: 10.1002/jps.24520. Epub 2015 Jun 10. J Pharm Sci. 2015. PMID: 26096711

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

71 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year